Clarity Pharmaceuticals Ltd

ASX:CU6 Stock Report

Market Cap: AU$2.2b

Clarity Pharmaceuticals Valuation

Is CU6 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CU6 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CU6's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CU6's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CU6?

Other financial metrics that can be useful for relative valuation.

CU6 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue183.2x
Enterprise Value/EBITDA-47.2x
PEG Ration/a

Price to Book Ratio vs Peers

How does CU6's PB Ratio compare to its peers?

The above table shows the PB ratio for CU6 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average8x
NEU Neuren Pharmaceuticals
8.4x-2.4%AU$1.8b
ALA Arovella Therapeutics
17.4xn/aAU$194.9m
MYX Mayne Pharma Group
0.8x110.0%AU$359.5m
BOT Botanix Pharmaceuticals
5.3x99.4%AU$581.6m
CU6 Clarity Pharmaceuticals
15.3x68.2%AU$2.2b

Price-To-Book vs Peers: CU6 is expensive based on its Price-To-Book Ratio (15.3x) compared to the peer average (8x).


Price to Earnings Ratio vs Industry

How does CU6's PE Ratio compare vs other companies in the AU Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a51.0%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a51.0%
n/an/an/a
No more companies

Price-To-Book vs Industry: CU6 is expensive based on its Price-To-Book Ratio (15.3x) compared to the Australian Pharmaceuticals industry average (4.6x).


Price to Book Ratio vs Fair Ratio

What is CU6's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CU6 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio15.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CU6's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CU6 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$7.01
AU$8.89
+26.9%
8.9%AU$10.00AU$8.20n/a3
Nov ’25AU$6.76
AU$8.89
+31.6%
8.9%AU$10.00AU$8.20n/a3
Oct ’25AU$8.72
AU$8.89
+2.0%
8.9%AU$10.00AU$8.20n/a3
Sep ’25AU$7.23
AU$8.89
+23.0%
8.9%AU$10.00AU$8.20n/a3
Aug ’25AU$6.50
AU$7.30
+12.3%
30.8%AU$10.00AU$4.50n/a3
Jul ’25AU$5.14
AU$3.87
-24.8%
15.0%AU$4.50AU$3.10n/a3
Jun ’25AU$5.08
AU$3.87
-23.9%
15.0%AU$4.50AU$3.10n/a3
May ’25AU$3.01
AU$3.37
+12.1%
11.0%AU$3.90AU$3.10n/a3
Apr ’25AU$2.75
AU$3.35
+21.9%
11.6%AU$3.90AU$3.05n/a3
Mar ’25AU$2.69
AU$3.12
+15.8%
10.8%AU$3.45AU$2.78n/a2
Feb ’25AU$2.28
AU$2.48
+8.6%
34.9%AU$3.35AU$1.30n/a3
Jan ’25AU$1.90
AU$2.19
+15.4%
34.5%AU$3.15AU$1.30n/a3
Dec ’24AU$1.36
AU$2.00
+47.0%
41.0%AU$3.15AU$1.30n/a3
Nov ’24AU$1.04
AU$1.82
+75.4%
31.1%AU$2.60AU$1.30AU$6.763
Oct ’24AU$1.17
AU$1.82
+55.2%
31.1%AU$2.60AU$1.30AU$8.723
Sep ’24AU$1.04
AU$1.71
+64.1%
37.1%AU$2.60AU$1.22AU$7.233
Aug ’24AU$0.89
AU$1.67
+88.0%
35.0%AU$2.50AU$1.22AU$6.503
Jul ’24AU$0.70
AU$1.71
+144.0%
33.1%AU$2.50AU$1.22AU$5.143
Jun ’24AU$0.76
AU$1.71
+126.2%
33.1%AU$2.50AU$1.22AU$5.083
May ’24AU$0.75
AU$1.69
+125.5%
34.0%AU$2.50AU$1.22AU$3.013
Apr ’24AU$0.75
AU$1.69
+125.5%
34.0%AU$2.50AU$1.22AU$2.753
Mar ’24AU$0.92
AU$1.69
+84.8%
34.0%AU$2.50AU$1.22AU$2.693
Feb ’24AU$0.83
AU$1.69
+103.7%
34.0%AU$2.50AU$1.22AU$2.283
Jan ’24AU$0.99
AU$1.66
+67.4%
31.9%AU$2.40AU$1.22AU$1.903
Dec ’23AU$0.97
AU$1.41
+45.0%
50.2%AU$2.40AU$0.82AU$1.363
Nov ’23AU$0.69
AU$1.41
+102.4%
50.2%AU$2.40AU$0.82AU$1.043

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies